Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Sportivumab - Feasibility of Exercise as a Supportive Measure for Patients Undergoing Checkpoint-inhibitor Treatment

NCT03171064 is registered in ClinicalTrials.gov with University Hospital Heidelberg as lead sponsor.

NCT NCT03171064
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03171064 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Sportivumab - Feasibility of Exercise as a Supportive Measure for Patients Undergoing Checkpoint-inhibitor Treatment
Lead sponsor
University Hospital Heidelberg
Phase
Phase 2
Overall status
Completed
Start date
September 5, 2017
Completion date
December 1, 2022
Enrollment
39 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

exercise, melanoma, pd-1 antibodies